31 results
425
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
21 Jun 22
Business combination disclosure
8:00am
approach $115 million of fully - committed equity financing provided to OmniAb Successful track record of building sustainable growth healthcare
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
21 Jun 22
Regulation FD Disclosure
6:19am
approach $115 million of fully - committed equity financing provided to OmniAb Successful track record of building sustainable growth healthcare
425
EX-99.3
1b4s2rx fxme32giao
23 Mar 22
Business combination disclosure
5:29pm
425
EX-99.2
inrz9pw901nbuprw2f0
23 Mar 22
Business combination disclosure
5:29pm
8-K
EX-99.3
gsmla1ngfcol2
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
8-K
EX-99.2
conkjuq4bx0xbqua5s
23 Mar 22
Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II
5:25pm
8-K
EX-99.1
h17on8n19y znlbx
13 Aug 14
Ligand Prices Offering of $225 Million of Convertible Senior Notes
12:00am
8-K
EX-99.1
87pdx98rv18nyf0
11 Aug 14
Ligand Announces Proposed Offering of $225 Million of Convertible Senior Notes
12:00am
8-K
EX-99.1
kmmj0 tbs4
11 Feb 14
Ligand Reports Fourth Quarter and Full Year 2013 Financial Results
12:00am
8-K
EX-99.1
a5cgf59 u6dc
4 Dec 13
Ligand Raises Fourth Quarter and Full Year 2013 Financial Forecast
12:00am
8-K
EX-99.1
opkz9z
30 Oct 13
Ligand Reports Third Quarter Financial Results
12:00am
8-K
EX-99.1
gvh4zef
24 Jul 13
Ligand Signs License Agreement with Ethicor for Oral Lasofoxifene
12:00am
8-K
EX-99.1
1yhusjoqd jrg8lzp
22 Jul 13
Ligand Signs Global License Agreement with Azure for Lasofoxifene
12:00am
8-K
EX-99.1
eov24s 9tdyy
20 Jun 13
Ligand Raises Ownership Limit for BVF Partners to 25% of Shares Outstanding
12:00am
8-K
EX-99.1
b0z9pyromjzxmmu
8 May 13
Ligand Reports First Quarter Financial Results
12:00am